Drugs / gaboxadol
gaboxadol
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03109756 | Apr → Nov 2017 | Angelman syndrome, fragile X syndrome | Healx AI | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06334419 | Jan 2024 → May 2025 | fragile X syndrome | Craig Erickson | Completed | No outcome recorded |
| Phase 2 | NCT03697161 | Sep 2018 → Feb 2020 | fragile X syndrome | Healx AI | Completed | No outcome recorded |
| Phase 2 | NCT02996305 | Jan 2016 → Jun 2018 | Angelman syndrome | Healx AI | Completed | No outcome recorded |
| Phase 2 | NCT00807248 | Nov 2008 → Dec 2009 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT00266357 | Nov 2005 → Mar 2007 | insomnia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 2 | NCT00266344 | Nov 2005 → Oct 2006 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT04106557 | Sep 2019 → Nov 2020 | Angelman syndrome | Healx AI | Completed | No outcome recorded |
| Phase 3 | NCT03882918 | Jan 2019 → Jun 2021 | Angelman syndrome | Healx AI | Terminated | No outcome recorded |
| Phase 3 | NCT00420810 | Sep 2006 → Mar 2007 | insomnia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00102167 | Feb → Dec 2005 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00103818 | Feb 2005 → Oct 2006 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00102154 | Jan 2005 → ? | insomnia | H. Lundbeck A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT00094666 | Nov 2004 → Mar 2007 | insomnia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00094627 | Nov 2004 → Apr 2006 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00095043 | Oct 2004 → Jun 2006 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00095069 | Oct 2004 → Feb 2007 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00209950 | Jul 2004 → Sep 2005 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00209846 | Jun 2004 → Nov 2006 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00209924 | Apr 2004 → Nov 2005 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00209963 | Jun 2003 → Mar 2005 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00209937 | Jan 2003 → Jun 2004 | insomnia | H. Lundbeck A/S | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04823052 Comparator | May → Oct 2022 | fragile X syndrome | Healx Limited | Withdrawn | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gaboxadol | “OBJECTIVE: To evaluate safety and tolerability and exploratory efficacy end points for gaboxadol (OV101) compared with placebo in individuals with Angelman syndrome (AS).” PMID 33443117 ↗ Dec 202019“MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)” NCT00266357 ↗ “Gaboxadol (OV101) is a δ-subunit-selective, extrasynaptic GABAA receptor agonist” PMID 34690787 ↗ Oct 2021 “MK0928, gaboxadol / Duration of Treatment: 10 months” NCT00102154 ↗ “MK0928, gaboxadol / Duration of Treatment - 6 weeks” NCT00094666 ↗ “MK0928, gaboxadol / Duration of Treatment 3 Weeks” NCT00266344 ↗ |
| Known as | HLX-0206 | “Gaboxadol (HLX-0206) Capsule” NCT04823052 ↗ |
| Known as | LU 02-030 | ChEMBL registry synonym — accepted as the source's own label CHEMBL312443 ↗ |
| Known as | MK0928 | “A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.” NCT00266357 ↗7“MK0928, gaboxadol / Duration of Treatment - 1 year” NCT00095069 ↗ “MK0928, gaboxadol” NCT00095043 ↗ |
| Known as | NSC-759585 | ChEMBL registry synonym — accepted as the source's own label CHEMBL312443 ↗ |
| Known as | OV101 | “OBJECTIVE: To evaluate safety and tolerability and exploratory efficacy end points for gaboxadol (OV101) compared with placebo in individuals with Angelman syndrome (AS).” PMID 33443117 ↗ Dec 20204“OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration” NCT04106557 ↗ |
| Action | Activate | “Gaboxadol is a highly selective orthosteric agonist that activates δ-subunit-containing extrasynaptic γ-aminobutyric acid type A (GABAA) receptors.” PMID 33443117 ↗ Dec 2020 |
| Modality | Small molecule | — CHEMBL312443 ↗ |
| Route | Oral | “The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome.” NCT02996305 ↗ |